Streetbeat News

CRVO

CervoMed Inc.

https://www.cervomed.com

Industry

Biotechnology

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

CervoMed (NASDAQ:CRVO) reported better-than-expected Q2 2024 results with an EPS of $(0.27) beating the estimate of $(0.42) and sales of $3.29 million surpassing the $2.08 million estimate.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 12:07 pm

CervoMed Inc. (NASDAQ:CRVO) presented plasma biomarker data from its AscenD-LB Phase 2a trial at the AAIC 2024, showing that neflamapimod treatment significantly reduced plasma GFAP levels in patients with dementia with Lewy bodies (DLB), correlating with improved clinical outcomes.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 12:13 pm

Morgan Stanley has initiated coverage on CervoMed (NASDAQ:CRVO) with an Overweight rating and a price target of $35.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2024 | 10:00 am

Canaccord Genuity analyst Sumant Kulkarni maintains a Buy rating on CervoMed (NASDAQ:CRVO) with a $65 price target.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 1:09 pm

CervoMed Inc. (NASDAQ:CRVO) will be added to the Russell 2000 and Russell 3000 Indexes effective July 1, 2024, as part of the annual reconstitution of the Russell U.S. Indexes.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 12:03 pm

CervoMed Inc. (NASDAQ:CRVO) has completed enrollment in its Phase 2b RewinD-LB clinical trial for neflamapimod, aimed at treating dementia with Lewy bodies. Topline data is expected in December 2024, and the trial design is optimized for success, potentially paving a clear path to market.

Portfolio Pulse from Benzinga Newsdesk

June 11, 2024 | 12:27 pm

Jones Trading has initiated coverage on CervoMed (NASDAQ:CRVO) with a Buy rating and set a price target of $70.

Portfolio Pulse from Benzinga Newsdesk

May 29, 2024 | 10:38 am

Virios Therapeutics shares fell 47.6% after pricing a $1.7 million public offering. Other notable movers include MultiMetaVerse Holdings, GT Biopharma, and Faraday Future Intelligent Electric, among others.

Portfolio Pulse from Avi Kapoor

May 20, 2024 | 5:28 pm

CervoMed Inc. (NASDAQ:CRVO) has appointed William Elder as Chief Financial Officer, effective June 1, 2024. Elder will also continue his roles as General Counsel and Corporate Secretary. He succeeds William Tanner, who will remain as a consultant.

Portfolio Pulse from Benzinga Newsdesk

May 20, 2024 | 12:04 pm

CervoMed (NASDAQ:CRVO) reported Q1 earnings per share (EPS) of $(0.41), missing the analyst estimate of $(0.39) by 5.13%. However, the company saw a significant improvement from the $(1.95) per share loss in the same period last year. Quarterly sales were $2.35 million, surpassing the analyst estimate of $1.35 million by 73.85%.

Portfolio Pulse from Benzinga Newsdesk

May 15, 2024 | 12:14 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.